REFERENCES
1. Shen, Z. X. et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354-60 (1997).
2. Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369, 111-21 (2013).
3. Kumthekar, P. et al. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. J. Neurooncol. 133, 589-94 (2017).
4. Balasundaram, N. et al. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Adv. 6, 652-63 (2022).
5. Bercier, P. et al. Structural basis of PML-RARA oncoprotein targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function. Cancer Discov. 13, 2548-65 (2023).
6. Yu, P. H.; Zhu, C. Y.; Kang, Y. Y.; Naranmandura, H.; Yang, C. Mutation in the unrearranged PML allele confers resistance to arsenic trioxide in acute promyelocytic leukemia. Research 8, 0696 (2025).
7. Hirano, S. Biotransformation of arsenic and toxicological implication of arsenic metabolites. Arch. Toxicol. 94, 2587-601 (2020).
8. Liu, Q. Toxicology of airborne inorganic arsenic: oxidative stress, molecular mechanisms, and organ-specific pathologies. Toxics 13, 753 (2025).
9. Qiu, T. et al. AS3MT facilitates NLRP3 inflammasome activation by m6A modification during arsenic-induced hepatic insulin resistance. Cell Biol. Toxicol. 39, 2165-81 (2023).
10. Ge, M. et al. Understanding and overcoming multidrug resistance in cancer. Nat. Rev. Clin. Oncol. 22, 760-80 (2025).
11. Tufail, M. et al. The hallmarks of oncogenic signaling: from pathways to resistance in cancer therapy. Drug Resist. Updat. 85, 101355 (2026).
12. Faubert, B.; Solmonson, A.; DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science 368, eaaw5473 (2020).
13. Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282-8 (2021).
14. Shim, M. K.; Yang, S.; Sun, I. C.; Kim, K. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer immunotherapy: preclinical evidence for safe and effective drug delivery. Adv. Drug Deliv. Rev. 183, 114177 (2022).
15. Guler Kara, H. et al. The G protein-coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. FEBS J. 292, 3755-70 (2025).
